| BCBS Illinois Medical Policies | Wheelchairs and Accessories | 2026-01-01 |
| UHC Surest Medical and Drug | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Gazyva® (Obinutuzumab) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Genetic Testing for Neurological Disorders – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Home Health, Skilled, and Custodial Care Services – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Natalizumab (Tyruko® & Tysabri®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Abnormal Uterine Bleeding and Uterine Fibroids – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Breast Reconstruction – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gazyva® (Obinutuzumab) – Commercial Medical Benefit Drug Policy | 2026-01-01 |